A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience

Authors: Costello, Brian A., Bhavsar, Nrupen A., Zakharia, Yousef, Pal, Sumanta K., Vaishampayan, Ulka, Jim, Heather, Fishman, Mayer N., Molina, Ana M., Kyriakopoulos, Christos E., Tsao, Che-Kai, Appleman, Leonard J., Gartrell, Benjamin A., Hussain, Arif, Stadler, Walter M., Agarwal, Neeraj, Pachynski, Russell K., Hutson, Thomas E., Hammers, Hans J., Ryan, Christopher W., Mardekian, Jack, Borham, Azah, George, Daniel J., Harrison, Michael R.

Source: Clinical genitourinary cancer. 20(1):1-10

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100167675040.0x000001&indx=1&recIds=ETOCvdc_100167675040.0x000001

Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer

Authors: Chatzkel, Jonathan, Schell, Michael J., Chahoud, Jad, Zhang, Jingsong, Jain, Rohit, Swank, Jennifer, Ludlow, Steve, Lombardi, Kristina, Lucas, Yesenia, Croft, Cortlin, Rembisz, Jennifer, Jameel, Gigi, Fishman, Mayer

Source: Clinical genitourinary cancer. 20(3):252-259

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100163573354.0x000001&indx=1&recIds=ETOCvdc_100163573354.0x000001

Updated efficacy, safety, and correlative analysis of a phase II trial in metastatic renal cell carcinoma with coordinated pembrolizumab and high dose IL-2.

Authors: Johnson, Jeffrey S, Fishman, Mayer N, Schell, Michael J, Yu, Xiaoqing, Wang, Xuefeng, Roman Souza, Gabriel, Miller, Justin, Mizelle, Sarah Raymond, Gullapalli, Keerthi, Fazili, Adnan Nazir, Guske, Christopher, Mannam, Gowtam, Jameel, Ghazal, Cen, Ling, Yao, Jiqiang, Whiting, Junmin, Swank, Jennifer, Zhang, Jingsong, Spiess, Philippe E., Chahoud, Jad

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p554-554, 177p

A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma

Authors: Hutson, Thomas E., Michaelson, M. Dror, Kuzel, Timothy M., Agarwal, Neeraj, Molina, Ana M., Hsieh, James J., Vaishampayan, Ulka N., Xie, Ran, Bapat, Urmi, Ye, Weifei, Jain, Rohit K., Fishman, Mayer N.

Source: In European Urology August 2021 80(2):162-170

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial

Authors: Atkins, Michael B., Plimack, Elizabeth R., Puzanov, Igor, Fishman, Mayer N., McDermott, David F., Cho, Daniel C., Vaishampayan, Ulka, George, Saby, Tarazi, Jamal C., Duggan, William, Perini, Rodolfo, Thakur, Mahgull, Fernandez, Kathrine C., Choueiri, Toni K.

Source: In European Journal of Cancer March 2021 145:1-10

Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findings

Authors: Hoogland, Aasha I., Jim, Heather S. L., Gonzalez, Brian D., Small, Brent J., Gilvary, Danielle, Breen, Elizabeth C., Bower, Julienne E., Fishman, Mayer, Zachariah, Babu, Jacobsen, Paul B.

Source: Cancer. 127(9):1476-1482

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100120260424.0x000001&indx=1&recIds=ETOCvdc_100120260424.0x000001

Investigating prostate cancer tumour-stroma interactions - clinical and biological insights from an evolutionary game

Authors: Basanta, David, Scott, Jacob G, Fishman, Mayer N, Ayala, Gustavo E, Hayward, Simon W, Anderson, Alexander RA

Subject Terms: Quantitative Biology - Populations and Evolution

Access URL: http://arxiv.org/abs/1108.0654

Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic.

Authors: Chatzkel, Jonathan, Fishman, Mayer, Ramnaraign, Brian, O'Malley, Padraic, Sonpavde, Guru P

Source: Research & Reports in Urology; Jul2024, Vol. 16, p161-176, 16p

Subject Terms: VASCULAR endothelial growth factor receptors, CLINICAL trials, RENAL cell carcinoma, PROTEIN-tyrosine kinase inhibitors, VASCULAR endothelial growth factor antagonists

Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience

Authors: Peyton, Charles C., Azizi, Mounsif, Chipollini, Juan, Ercole, Cesar, Fishman, Mayer, Gilbert, Scott M., Juwono, Timothy, Lockhart, Jorge, Poch, Michael, Pow-Sang, Julio M., Spiess, Philippe E., Wiegand, Lucas, Sexton, Wade J.

Source: In Clinical Genitourinary Cancer October 2018 16(5):e1003-e1013

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

Authors: Atkins, Michael B ^*, Plimack, Elizabeth R, Puzanov, Igor, Fishman, Mayer N, McDermott, David F, Cho, Daniel C, Vaishampayan, Ulka, George, Saby, Olencki, Thomas E, Tarazi, Jamal C, Rosbrook, Brad, Fernandez, Kathrine C, Lechuga, Mariajose, Choueiri, Toni K

Source: In The Lancet Oncology March 2018 19(3):405-415

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

Authors: Voss, Martin H., Bhatt, Rupal S., Vogelzang, Nicholas J., Fishman, Mayer, Alter, Robert S., Rini, Brian I., Beck, J. Thaddeus, Joshi, Monika, Hauke, Ralph, Atkins, Michael B., Burgess, Earle, Logan, Theodore F., Shaffer, David, Parikh, Rahul, Moazzam, Nauman, Zhang, Xiaosha, Glasser, Chad, Sherman, Matthew L., Plimack, Elizabeth R.

Source: Cancer. 125(14):2400-2408

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100084329548.0x000001&indx=1&recIds=ETOCvdc_100084329548.0x000001

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Authors: Buchbinder, Elizabeth, Dutcher, Janice, Daniels, Gregory, Curti, Brendan, Patel, Sapna, Holtan, Shernan, Miletello, Gerald, Fishman, Mayer, Gonzalez, Rene, Clark, Joseph, Richart, John, Lao, Christopher, Tykodi, Scott, Silk, Ann, McDermott, David

Source: Journal for immunotherapy of cancer. 7(1):1-7

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100186497014.0x000001&indx=1&recIds=ETOCvdc_100186497014.0x000001

Therapeutic agent applicators and methods of using the same

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM

Authors: Clark, Joseph I., Wong, Michael K.K., Kaufman, Howard L., Daniels, Gregory A., Morse, Michael A., McDermott, David F., Agarwala, Sanjiv S., Lewis, Lionel D., Stewart, John H., Vaishampayan, Ulka, Curti, Brendan, Gonzalez, René, Lutzky, Jose, Rudraptna, Venkatesh, Cranmer, Lee D., Jeter, Joanne M., Hauke, Ralph J., Miletello, Gerald, Milhem, Mohammed M., Amin, Asim, Richart, John M., Fishman, Mayer, Hallmeyer, Sigrun, Patel, Sapna P., Van Veldhuizen, Peter, Agarwal, Neeraj, Taback, Bret, Treisman, Jonathan S., Ernstoff, Marc S., Perritt, Jessica C., Hua, Hong, Rao, Tharak B., Dutcher, Janice P., Aung, Sandra

Source: In Clinical Genitourinary Cancer February 2017 15(1):31-41

Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma

Authors: Kis, Bela, Shah, Jehan, Choi, Junsung, El-Haddad, Ghassan, Sweeney, Jennifer, Biebel, Benjamin, Mellon, Eric, Frakes, Jessica M., Hoffe, Sarah E., Fishman, Mayer N., Shridhar, Ravi

Source: In Journal of Vascular and Interventional Radiology February 2017 28(2):254-259

Sociodemographic and Provider Based Disparities in the Management of Stage I Testicular Cancer

Authors: Agarwal, Gautum, Sharma, Pranav, Valderrama, Oscar, Lin, Hui-Yi, Yue, Binglin, Nguyen, Sabine, Fishman, Mayer, Luchey, Adam, Pow-Sang, Julio M., Spiess, Philippe E., Poch, Michael A., Sexton, Wade J.

Source: In Urology Practice January 2017 4(1):36-42

Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment

Authors: González, Juan Marcos, Doan, Justin, Gebben, David J., Boeri, Marco, Fishman, Mayer

Source: PharmacoEconomics. 36(8):973-986

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100130220580.0x000001&indx=1&recIds=ETOCvdc_100130220580.0x000001

Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma

Authors: Rini, Brian I., Tomita, Yoshihiko, Melichar, Bohuslav, Ueda, Takeshi, Grünwald, Viktor, Fishman, Mayer N., Uemura, Hirotsugu, Oya, Mototsugu, Bair, Angel H., Andrews, Glen I., Rosbrook, Brad, Jonasch, Eric

Source: In Clinical Genitourinary Cancer December 2016 14(6):499-503

Evaluation of the psychometric properties of the PROMIS Cancer Fatigue Short Form with cancer patients

Authors: Cessna, Julie M., Jim, Heather S.L., Sutton, Steven K., Asvat, Yasmin, Small, Brent J., Salsman, John M., Zachariah, Babu, Fishman, Mayer, Field, Teresa, Fernandez, Hugo, Perez, Lia, Jacobsen, Paul B.

Source: In Journal of Psychosomatic Research February 2016 81:9-13

Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison

Authors: Gonzalez, Brian D., Jim, Heather S.L., Donovan, Kristine A., Small, Brent J., Sutton, Steve K., Park, Jong, Lin, Hui-Yi, Spiess, Philippe E., Fishman, Mayer N., Jacobsen, Paul B.

Source: In The Journal of Urology September 2015 194(3):690-695